![]() |
Fostamatinib disodium
- 英文名称:Fostamatinib disodium
- 品牌:WYTSCI
- 产地:进口
- 型号:1MG
- 货号:WT-AY-B11132
- cas:1025687-58-4
- 价格: ¥1/mg
- 发布日期: 2025-04-10
- 更新日期: 2025-05-23
产品详请
产地 | 进口 |
品牌 | WYTSCI |
货号 | WT-AY-B11132 |
用途 | 科研检测 |
英文名称 | Fostamatinib disodium |
包装规格 | 1MG |
CAS编号 | 1025687-58-4 |
别名 | Fostamatinib disodium |
纯度 | 98+% |
分子式 | |
是否进口 | 是 |
纯度:>98% by HPLC;NMR (Conforms)
分子式:C23H24FN6O9P·2Na
分子量:624.43
溶剂:DMSO (12 mg/ml with warming)
性状:White solid
存储:-20°C
Activity (short version):Syk inhibitor
Function / Pharmacology:Fostamatinib is a prodrug of the spleen tyrosine kinase inhibitor (Syk) R406 and is approved for the treatment of chronic immune thrombocytopenia. It has demonstrated significant reduction in inflammatory mediators such as TNFα, IL-1, IL-6, and IL-8 in arthritis models.1 Syk IC50 = 41 nM – Fostamatinib also inhibits Flt3, Lyn, and Lck with similar potency in vitro but displays higher selectivity Syk in cellular assays.2 Significantly inhibits LPS-induced inflammatory response via blocking STAT1/3 signaling.3 Fostamatinib restored myeloid homeostasis in severe COVID-19.4 Displayed synergistic effects with anti-PDL1 therapy against neuroblastoma.5 Fostamatinib induces metabolic reprogramming of acute myeloid leukemia stem cells.6
分子式:C23H24FN6O9P·2Na
分子量:624.43
溶剂:DMSO (12 mg/ml with warming)
性状:White solid
存储:-20°C
Activity (short version):Syk inhibitor
Function / Pharmacology:Fostamatinib is a prodrug of the spleen tyrosine kinase inhibitor (Syk) R406 and is approved for the treatment of chronic immune thrombocytopenia. It has demonstrated significant reduction in inflammatory mediators such as TNFα, IL-1, IL-6, and IL-8 in arthritis models.1 Syk IC50 = 41 nM – Fostamatinib also inhibits Flt3, Lyn, and Lck with similar potency in vitro but displays higher selectivity Syk in cellular assays.2 Significantly inhibits LPS-induced inflammatory response via blocking STAT1/3 signaling.3 Fostamatinib restored myeloid homeostasis in severe COVID-19.4 Displayed synergistic effects with anti-PDL1 therapy against neuroblastoma.5 Fostamatinib induces metabolic reprogramming of acute myeloid leukemia stem cells.6